IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
Research To Practice | Oncology Videos · Dr. Neil Love
June 24, 202554m 7s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Patrick Y Wen, including the following topics:
- Glioma classification (0:00)
- Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50)
- Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55)
- Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46)
- Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30)
- Current and emergent strategies for the management of glioblastoma (31:27)
- Optimizing patient care and quality of life (46:24)